Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2001-06-26 Legal Proceedings Report
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys AG deutsch
Legal Proceedings Report Classification · 99% confidence The document is a short 'Ad-hoc-Mitteilung' (Ad-hoc announcement) dated June 26, 2001, detailing a specific operational milestone achieved by MorphoSys AG with DuPont Pharmaceuticals regarding their AutoCAL system. It announces a specific event (milestone achievement and associated payment) rather than providing comprehensive financial results (ER/IR/10-K), management changes (MANG), or a general regulatory update. Since it is a specific, non-standard announcement about a business development (collaboration milestone), and it doesn't fit perfectly into the other specific categories like DIV, CAP, or TAR, the most appropriate general category for specific, non-routine corporate news that isn't a standard financial report or insider trade is the fallback category, Regulatory Filings (RNS). The document length is very short (1155 chars), supporting the idea that it is an announcement rather than a full report.
2001-06-26 German
MorphoSys AG english
Regulatory Filings Classification · 95% confidence The document is very short (1165 characters) and is explicitly labeled as an 'Ad hoc announcement' transmitted by DGAP. It details a specific business event (achieving a milestone with DuPont Pharmaceuticals) and mentions receiving a payment, which is typical for a general regulatory disclosure that doesn't fit a specific financial reporting category like 10-K, ER, or IR. Since it is a general, non-standard announcement that doesn't fit the specific categories (like DIV, DIRS, MANG, etc.), the most appropriate fallback category is Regulatory Filings (RNS).
2001-06-26 English
MorphoSys AG deutsch
Legal Proceedings Report Classification · 98% confidence The document is an 'Ad-hoc-Mitteilung' (Ad-hoc announcement) dated June 21, 2001, detailing a patent infringement lawsuit filed against MorphoSys AG by Cambridge Antibody Technology Ltd. (CAT) and others in the US District Court. This content specifically concerns legal action and regulatory/litigation matters involving the company. Based on the definitions, 'Legal Proceedings Report (LTR)' is the most appropriate category for updates on significant lawsuits or regulatory actions. The document is short and is an announcement of the legal event, not a comprehensive legal filing itself.
2001-06-21 German
MorphoSys AG english
Legal Proceedings Report Classification · 98% confidence The document is a short 'Ad hoc announcement' dated June 21, 2001, detailing that MorphoSys AG confirmed the filing of a patent lawsuit against it by Cambridge Antibody Technology (CAT) regarding US Patent No. 6,248,516. This content specifically concerns a significant legal matter involving patent infringement claims. Based on the definitions, the category 'Legal Proceedings Report (Code: LTR)' is the most appropriate fit, as it covers 'Updates on significant lawsuits, regulatory actions, or legal matters involving the company.' The document is not a comprehensive financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific update on litigation.
2001-06-21 English
MorphoSys AG english
M&A Activity Classification · 99% confidence The document is very short (1160 characters) and is explicitly labeled as an 'Ad-hoc announcement' processed by DGAP. It details a specific business event: the expansion of a research collaboration and licensing agreement between MorphoSys AG and ImmunoGen, including financial terms (fees). This type of specific, immediate corporate action announcement that doesn't fit neatly into standard periodic reports (like 10-K, IR, ER) or specific shareholder actions (like DIV, DVA) is best classified as a general Regulatory Filing (RNS), which serves as a broad category for ad-hoc disclosures not covered elsewhere. It is not a presentation (AGM-R), a full report (10-K, IR), or a management change (MANG).
2001-06-21 English
MorphoSys AG deutsch
M&A Activity Classification · 99% confidence The document is a short 'Ad-hoc-Mitteilung' (Ad-hoc announcement) dated June 21, 2001, detailing a business agreement (licensing expansion) between MorphoSys AG and ImmunoGen, Inc. It announces a corporate event (a licensing deal) rather than being a full financial report (like 10-K or IR) or a standard regulatory filing like a director's dealing or dividend notice. Since it is a specific corporate action announcement that doesn't fit the other specialized categories (like M&A, Capital Change, or Earnings Release), it falls best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous official announcements, or potentially 'Capital/Financing Update' if the deal structure was purely financial, but 'RNS' is the most appropriate general regulatory announcement bucket here, as it is an 'Ad-hoc' news item.
2001-06-21 German

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.